Bacille Calmette-Guérin vaccination: The current situation in Europe

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 24-35

  Dara, Masoud ^a   Acosta, Colleen D ^a   Rusovich, Valiantsin ^a   Zellweger, Jean Pierre ^b   Centis, Rosella ^a   Migliori, Giovanni Battista ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Swiss Lung Association   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; TUBERCULOSTATIC AGENT;

BACTERIAL STRAIN; BCG VACCINATION; CZECHOSLOVAKIA; DEVELOPING COUNTRY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EUROPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INCIDENCE; INFECTION; INJECTION SITE ABSCESS; INJECTION SITE REACTION; LUNG TUBERCULOSIS; LYMPHADENITIS; MORBIDITY; MORTALITY; POINT MUTATION; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKIN ULCER; SWEDEN; TUBERCULOSIS; TUBERCULOUS MENINGITIS; WESTERN EUROPE;

BCG VACCINE; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84891927893     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00113413     Document Type: Review

References (58)

1. World Health Organization. Global tuberculosis report 2012. Document WHO/HTM/TB/2012.6. Geneva, World Health Organization, 2012.
2. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm, European Centre for Disease Prevention and Control, 2013.
3. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: Progress and new developments. Lancet 2012; 379: 1902-1913.
4. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: The ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
5. WHO Regional Office for Europe. Roadmap to Prevent and Combat Drug-resistant Tuberculosis. The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-resistant Tuberculosis in the Who European Region, 2011-2015. Geneva, World Health Organization, 2012.
6. Rieder HL, Epidemiologic basis of tuberculosis control. Paris, International Union Against Tuberculosis and Lung Disease, 1999.
7. Migliori GB, Sotgiu G, Lange C, et al. Extensively drug-resistant tuberculosis: Back to the future. Eur Respir J 2010; 36: 475-477.
8. Diel R, Goletti D, Ferrara G, et al. Interferon-c release assays for the diagnosis of latent Mycobacterium tuberculosis infection: A systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
9. Sester M, Sotgiu G, Lange C, et al. Interferon-c release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
10. Weyer K, Mirzayev F, Migliori G, et al. Rapid molecular TB diagnosis: Evidence, policy-making and global implementation of Xpert1MTB/RIF. Eur Respir J 2013; 42: 252-271.
11. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: Update 2010. Eur Respir J 2010; 37: 441-462.
12. World Health Organization. The treatment of tuberculosis guidelines. Document WHO/HTM/TB/2009.420. Geneva, World Health Organization, 2010.
13. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
14. Blasi F, Reichman LB, Migliori GB. Presenting the European Forum for TB Innovation: Innovative thinking in progressing towards TB elimination in Europe. Eur Respir J 2012; 40: 806-808.
15. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate TB control: Preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
16. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: The history of the Wolfheze Workshops. Eur Respir J 2011; 37: 950-959.
17. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79: 27-38.
18. World Health Organization. BCG (Tuberculosis). www.who.int/biologicals/ areas/vaccines/bcg/Tuberculosis/en/Date last accessed: June 7, 2013. Date last updated: June 28, 2012.
19. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
20. Stýblo K, Danková D, Drápela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Report for the firstt years of the study (1961-64). Bull World Health Organ 1967; 37: 819-874.
21. Romanus V. First experience with BCG discontinuation in Europe. Experience in Sweden 15 years after stopping general BCG vaccination at birth. Bull Int Union Tuberc Lung Dis 1990; 65: 32-35.
22. Trnka L, Dankova D, Zitova J, et al. Survey of BCG vaccination policy in Europe: 1994-96. Bull World Health Organ 1998; 76: 85-91.
23. WHO vaccine-preventable diseases: Monitoring system. 2013 global summary. http://apps.who.int/immunization- monitoring/globalsummary/schedules Date last accessed: July 3, 2013.
24. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. www.bcgatlas.org/index.php Date last accessed: July 3, 2013.
25. WHO Regional Office for Europe. Childhood TB Taskforce Survey on BCG Practices. Geneva, World Health Organization, 2013.
26. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-1018.
27. WHO Regional Office for Europe. WHO/ECDC joint support mission to Romania to assess reports of adverse events following immunization with a BCG vaccine in current use. Geneva, World Health Organization, 2012.
28. Oettinger T, Jørgensen M, Ladefoged A, et al. Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 1999; 79: 243-250.
29. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th Edn. Philadelphia, Elsevier Saunders, 2013.
30. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: A review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68: 93-108.
31. World Health Organization. Immunization standards. Prequalification of vaccines. www.who.int/immunization- standards/vaccine-quality/vq-index/en/index. html Date last accessed: July 3, 2013. Date last updated: May 24, 2012.
32. Nuttall JJC, Eley BS. BCG Vaccination in HIV-Infected Children. Tuberc Res Treat 2011; 2011: 712-736.
33. Cuello-Garća CA, Pérez-Gaxiola G, Jiménez Gutiérrez C. Treating BCG-induced disease in children. Cochrane Database Syst Rev 2013; 1: CD008300.
34. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIVinfected children. Vaccine 2007; 25: 14-18.
35. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIVuninfected children. Clin Infect Dis 2006; 42: 548-558.
36. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82: 193-196.
37. Vallishayee RS, Shashidhara AN, Bunch-Christensen K, et al. Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. Bull World Health Organ 1974; 51: 489-494.
38. World Health Organization. Information Sheet, Observed rate of vaccine reactions of Bacillus Calmette-Guérin (BCG) vaccine. Geneva, World Health Organization, 2012.
39. Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Guérin. Clin Infect Dis 2002; 34: 447-453.
40. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCGvaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 47-59.
41. Hesseling AC, Johnson LF, Jaspan H, et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87: 505-511.
42. Mak TK, Hesseling AC, Hussey GD, et al. Making BCG vaccination programmes safer in the HIV era. Lancet 2008; 372: 786-787.
43. Nuttall JJ, Davies M-A, Hussey GD, et al. Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12: E99-e105.
44. Caglayan S, Yegin O, Kayran K, et al. Is medical therapy effective for regional lymphadenitis following BCG vaccination Am J Dis Child 1987; 141: 1213-1214.
45. Ritz N, Tebruegge M, Connell TG, et al. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother 2009; 53: 316-318.
46. World Health Organization. Isoniazid resistance of bacille Calmette-Guérin strains. Wkly Epidemiol Rec 2005; 80: 241-248.
47. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: Implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23: 476-479.
48. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis 1994; 75: 179-180.
49. Altes HK, Dijkstra F, Lugnèr A, et al. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: Epidemiologic and economic assessment. Epidemiology 2009; 20: 562-568.
50. Migliori GB, Raviglione MC, Schaberg T, et al. Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978-992.
51. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
52. Dara M, de Colombani P, Petrova-Benedict R, et al. Minimum package for cross-border TB control and care in the WHO European region: A Wolfheze consensus statement. Eur Respir J 2012; 40: 1081-1090.
53. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
54. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: Results from a large individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
55. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: Impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
56. Migliori GB, Sotgiu G, Blasi F, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J 2011; 38: 493-495.
57. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
58. Sandgren A, Cuevas LE, Dara M, et al. Childhood tuberculosis: Progress requires an advocacy strategy now. Eur Respir J 2012; 40: 294-297.